Dual-targeting conjugates designed to improve the efficacy of radiolabeled peptides.
Radiolabeled regulatory peptides are useful tools in nuclear medicine for the diagnosis (imaging) and therapy of cancer. The specificity of the peptides towards GPC receptors, which are overexpressed by cancer cells, and their favorable pharmacokinetic profile make them ideal vectors to transport conjugated radionuclides to tumors and metastases. However, after internalization of the radiopeptide into cancer cells and tumors, a rapid washout of a substantial fraction of the delivered radioactivity is often observed. This phenomenon may represent a limitation of radiopeptides for clinical applications. Here, we report the synthesis, radiolabeling, stability, and in vitro evaluation of a novel, dual-targeting peptide radioconjugate designed to enhance the cellular retention of radioactivity. The described trifunctional conjugate is comprised of a Tc-99m SPECT reporter probe, a cell membrane receptor-specific peptide, and a second targeting entity directed towards mitochondria. While the specificity of the first generation of dual-targeting conjugates towards its extracellular target was demonstrated, intracellular targeting could not be confirmed probably due to non-specific binding or hindered passage through the membrane of the organelle. The work presented describes a novel approach with potential to improve the efficacy of radiopharmaceuticals by enhancing the intracellular retention of radioactivity.
University of Basel Hospital, Department of Radiology and Nuclear Medicine, Division of Radiological Chemistry, Petersgraben 4, 4031 Basel, Switzerland.
Christiane A
CA
Kluba
Andreas
A
Bauman
Ibai E
IE
Valverde
Sandra
S
Vomstein
Thomas L
TL
Mindt
D016503:Drug Delivery Systems; D015195:Drug Design; D006801:Humans; D008928:Mitochondria / Q000378:metabolism; D010455:Peptides / Q000138:chemical synthesis / Q000737:chemistry / Q000378:metabolism*; D019275:Radiopharmaceuticals / Q000138:chemical synthesis / Q000737:chemistry / Q000378:metabolism*; D012211:Rhenium / Q000737:chemistry*; D013379:Substrate Specificity; D013667:Technetium / Q000737:chemistry*; D014407:Tumor Cells, Cultured
D010455:Peptides; D019275:Radiopharmaceuticals; D012211:Rhenium; D013667:Technetium